Product description
Insumate® bitter melon extract contains the patented amino peptide sequence mcIRBP-19, which is a scientific-recognized active compound for glucose modulation. The clinical efficacy of Insumate® has been validated by two officially clinical studies. It is easy to be absorbed by human body due to the low molecular weight of mcIRBP-19. The underlying mechanism of glucose modulation has been verified by in-vitro and animal models.
Insumate® (NDIN No. 1256) is the first USFDA-approved bitter melon product.
Insumate® is produced by a unique fabrication process at low temperatures to ensure the product quality and remain the activity of mcIRBP-19. Currently, Greenyn is the only provider and ODM for Insumate®-associated products.
Read more